206 related articles for article (PubMed ID: 24916907)
1. Critique of Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation trial.
Veltkamp R; Prabhakaran S
Stroke; 2014 Jul; 45(7):2151-3. PubMed ID: 24916907
[No Abstract] [Full Text] [Related]
2. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
Ruff CT; Giugliano RP; Antman EM; Crugnale SE; Bocanegra T; Mercuri M; Hanyok J; Patel I; Shi M; Salazar D; McCabe CH; Braunwald E
Am Heart J; 2010 Oct; 160(4):635-41. PubMed ID: 20934556
[TBL] [Abstract][Full Text] [Related]
3. Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial.
Eisen A; Giugliano RP; Ruff CT; Nordio F; Gogia HS; Awasty VR; Henderson DA; Mercuri MF; Rutman H; Antman EM; Braunwald E
Am Heart J; 2016 Feb; 172():144-51. PubMed ID: 26856226
[TBL] [Abstract][Full Text] [Related]
4. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
Giugliano RP; Ruff CT; Rost NS; Silverman S; Wiviott SD; Lowe C; Deenadayalu N; Murphy SA; Grip LT; Betcher JM; Duggal A; Dave J; Shi M; Mercuri M; Antman EM; Braunwald E;
Stroke; 2014 Aug; 45(8):2372-8. PubMed ID: 24947287
[TBL] [Abstract][Full Text] [Related]
5. Once-daily edoxaban: a safer option than well-managed warfarin for patients with atrial fibrillation?
Giugliano RP
Eur Heart J; 2014 Jul; 35(28):1826-7. PubMed ID: 25184175
[No Abstract] [Full Text] [Related]
6. Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves.
Carnicelli AP; De Caterina R; Halperin JL; Renda G; Ruff CT; Trevisan M; Nordio F; Mercuri MF; Antman E; Giugliano RP;
Circulation; 2017 Mar; 135(13):1273-1275. PubMed ID: 28209729
[No Abstract] [Full Text] [Related]
7. Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction).
Aisenberg J; Chatterjee-Murphy P; Friedman Flack K; Weitz JI; Ruff CT; Nordio F; Mercuri MF; Choi Y; Antman EM; Braunwald E; Giugliano RP
Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e003998. PubMed ID: 29748353
[TBL] [Abstract][Full Text] [Related]
8. Quality of anticoagulation control in atrial fibrillation.
Lane DA; Lip GY
Lancet; 2010 Sep; 376(9745):935-7. PubMed ID: 20801499
[No Abstract] [Full Text] [Related]
9. Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48.
Plitt A; Ezekowitz MD; De Caterina R; Nordio F; Peterson N; Giugliano RP;
Clin Cardiol; 2016 Jun; 39(6):345-6. PubMed ID: 27028520
[No Abstract] [Full Text] [Related]
10. Edoxaban or standard therapy with warfarin for stroke prevention in patients with atrial fibrillation?
Plitt A; Giugliano RP
Future Cardiol; 2014 Mar; 10(2):153-5. PubMed ID: 24762238
[No Abstract] [Full Text] [Related]
11. Dabigatran: safer, more effective and easier to use than warfarin.
Cardiovasc J Afr; 2009; 20(5):311-2. PubMed ID: 19907807
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of oral direct factor Xa inhibitors versus warfarin in patients with atrial fibrillation: a meta-analysis of randomized controlled trials.
Xiang CL; Gong YZ; Zeng LJ; Wang R; Kea S; Chaudhary N; Tu RH; He Y
Acta Cardiol; 2016 Jun; 71(3):349-57. PubMed ID: 27594130
[No Abstract] [Full Text] [Related]
13. [New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
Koziński M; Obońska K; Kubica A; Navarese EP; Kubica J
Kardiol Pol; 2012; 70(10):1053-60. PubMed ID: 23080100
[No Abstract] [Full Text] [Related]
14. Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial.
Ruff CT; Giugliano RP; Braunwald E; Mercuri M; Curt V; Betcher J; Grip L; Cange AL; Crompton AE; Murphy SA; Deenadayalu N; Antman EM
J Am Coll Cardiol; 2014 Aug; 64(6):576-84. PubMed ID: 25104527
[TBL] [Abstract][Full Text] [Related]
15. Edoxaban in patients with atrial fibrillation.
Eisen A; Ruff CT
Ther Adv Cardiovasc Dis; 2017 Mar; 11(3):81-90. PubMed ID: 26680560
[TBL] [Abstract][Full Text] [Related]
16. Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.
Piccini JP; Lopes RD; Mahaffey KW
Curr Opin Cardiol; 2010 Jul; 25(4):312-20. PubMed ID: 20520539
[TBL] [Abstract][Full Text] [Related]
17. Spontaneous conversion in patients with non-valvular atrial fibrillation planned for electrical cardioversion: A subanalysis of the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion Of Atrial Fibrillation (ENSURE-AF) trial.
Cohen AA; Heidbuchel H; Le Heuzey JY; De Caterina R; Merino JL; Jin J; Melino M; Winters SM; Goette A; Lip GYH
Am Heart J; 2019 Mar; 209():131-135. PubMed ID: 30635112
[No Abstract] [Full Text] [Related]
18. [The ENGAGE AF-TIMI 48 study].
Rubboli A; Colonna P
G Ital Cardiol (Rome); 2015 Sep; 16(9):457-61. PubMed ID: 26418383
[No Abstract] [Full Text] [Related]
19. Another novel oral anticoagulant matches warfarin.
Mitka M
JAMA; 2014 Jan; 311(3):233-4. PubMed ID: 24430308
[No Abstract] [Full Text] [Related]
20. Edoxaban for atrial high-rate episodes: more harm than good?
Liuzzo G; Patrono C
Eur Heart J; 2024 Feb; 45(5):330-331. PubMed ID: 38073245
[No Abstract] [Full Text] [Related]
[Next] [New Search]
